Did Embecta's 52% Fall Catch You Out? What Investors Missed

If you had backed Embecta at the start of this review period expecting GLP-1 partnerships and efficiency gains to do the heavy lifting, the outcome looked very different on your statement. Investors who held Embecta over the past year are down 51.6%, including dividends. The return is clear, so what part of the original case around gently declining revenue, sharply higher profit margins, and a lower 2028 P/E multiple did not allow for how this actually played out?

A Narrative on Simply Wall St is one investor's written case for a company, with its growth, margin and multiple assumptions spelled out. Those assumptions imply an estimated Fair Value.

If the move has made Embecta harder to judge, start where the gap is still open and scan 29 high quality undervalued stocks.

The Two Embecta Stories Investors Had To Weigh

The shares cost US$14.14 at the start of the period, and Embecta sat between two very different but reasonable stories about its future.

The bullish Narrative saw Fair Value at US$16.67, built on GLP-1 partnerships and gently declining revenue growth of 0.3% with profit margins rising to 16.7% on a 7.4x future P/E assumption.

The bearish view put Fair Value at US$11.83. That case leaned on tightening reimbursement and structural pressure on legacy insulin delivery products, even while assuming margins climbing to 17.5% and a much lower 4.7x future P/E.

What The Embecta Evidence Actually Tested

Embecta’s Q3 2026 numbers challenged the optimistic margin story. Revenue moved from US$295.5m in Q3 2025 to US$271.7m, while net income excluding extra items went from US$45.5m to US$21.1m. Net margin fell from 15.4% to 7.8%. Those figures leaned toward the cautious case that questioned how durable profitability improvements would really be.

The episode turned on one assumption: that margins could rise even if sales softened. For any other stock built on that promise, track net income and net margin together against the original thesis each quarter.

What Embecta's Lower Price Asks You To Believe

Embecta trades at US$6.71 today, while the selected Narrative’s Fair Value sits below that level. The argument is less about collapse and more about whether GLP-1 partnerships, auto-injectors and the Owen Mumford deal can carry enough weight as the older U.S. pen needle line faces pressure.

The same Narrative flags a key judgment call for anyone buying now. You would need to test whether ongoing U.S. reimbursement and pricing risk is fully reflected in a lower price or still underappreciated.

"The current numbers and litigation overhang imply a share price that still embeds generous expectations for Embecta’s diversification and margin recovery, which this bearish narrative views as overvalued."

One Narrative disagrees with today's price. → See where this Narrative says Embecta should trade

Which Company Could Surprise You Next?

Passing on this one could have spared you a loss. Where might you find the opposite surprise? Start looking for companies whose prices leave room for a better outcome than investors expect. These three trade below our estimated value.

• Company 1 - 33% below our estimate - turns subsea project leads into bundled installation work and multi-phase services engagements.
• Company 2 - 24% below our estimate - ties AI-focused computing needs to integrated cloud, productivity, developer and security offerings.
• Company 3 - 37% below our estimate - tackles difficult technical, safety and regulatory issues via multidisciplinary science and engineering advice.

That is three of the list. See the full list of 24 financially solid companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com